The DOI matches its Crossref record; 203 of the 207 references it cites were found in a registry or an index; 164 of the 253 sources its claims cite were checked for support.
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Open accessAbstract
Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events. Consequently, novel pharmaceutical drugs have been developed to control and modify the composition of blood lipids to ultimately prevent fatal cardiovascular events in patients with dyslipidaemia. This article reviews established and emerging lipid-lowering drugs regarding their mechanism of action, development stage, ongoing clinical trials, side effects, effect on blood lipids and reduction in cardiovascular morbidity and mortality. We conducted a keyword search to identify studies on established and emerging lipid modifying drugs. Results were summarized in a narrative overview. Established pharmaceutical treatment options include the Niemann-Pick-C1 like-1 protein (NPC1L1) inhibitor ezetimibe, the protein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab, fibrates as peroxisome proliferator receptor alpha (PPAR-α) activators, and the omega-3 fatty acid icosapent ethyl. Statins are recommended as the first-line therapy for primary and secondary cardiovascular prevention in patients with hypercholesterinaemia and hypertriglyceridemia. For secondary prevention in hypercholesterinaemia, second-line options such as statin add-on or statin-intolerant treatments are ezetimibe, alirocumab and evolocumab. For secondary prevention in hypertriglyceridemia, second-line options such as statin add-on or statin-intolerant treatments are icosapent ethyl and fenofibrate. Robust data for these add-on therapeutics in primary cardiovascular prevention remains scarce. Recent biotechnological advances have led to the development of innovative small molecules (bempedoic acid, lomitapide, pemafibrate, docosapentaenoic and eicosapentaenoic acid), antibodies (evinacumab), antisense oligonucleotides (mipomersen, volanesorsen, pelcarsen, olezarsen), small interfering RNA (inclisiran, olpasiran), and gene therapies for patients with dyslipidemia. These molecules specifically target new cellular pathways, such as the adenosine triphosphate-citrate lyase (bempedoic acid), PCSK9 (inclisiran), angiopoietin-like 3 (ANGPTL3: evinacumab), microsomal triglyceride transfer protein (MTP: lomitapide), apolipoprotein B-100 (ApoB-100: mipomersen), apolipoprotein C-III (ApoC-III: volanesorsen, olezarsen), and lipoprotein (a) (Lp(a): pelcarsen, olpasiran). The authors are hopeful that the development of new treatment modalities alongside new therapeutic targets will further reduce patients' risk of adverse cardiovascular events. Apart from statins, data on new drugs' use in primary cardiovascular prevention remain scarce. For their swift adoption into clinical routine, these treatments must demonstrate safety and efficacy as well as cost-effectiveness in randomized cardiovascular outcome trials.
Overview
CoChat Summary
TL;DR
This narrative review summarizes established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention, with emphasis on mechanisms, trial results, side effects, and guideline positioning. It concludes that statins remain first-line, while newer agents such as bempedoic acid, inclisiran, pelacarsen, and olpasiran may expand treatment options but still need stronger outcomes and cost-effectiveness data.
Key findings
- Statins are first-line therapy; a 1 mmol/L LDL-C reduction was associated with a 22% lower risk of MACE, and low-/moderate-intensity statins reduced MACE by 22% (95% CI 19–24), with an additional 15% reduction from intensification.
- Ezetimibe added to simvastatin in 18,144 post-ACS patients reduced MACE by 6% (95% CI 1–11, p = 0.016); in EWTOPIA 75, ezetimibe monotherapy in 3,796 patients aged ≥75 years reduced MACE by 34% (HR 0.66, 95% CI 0.50–0.86, p = 0.002).
- PCSK9 inhibitors reduced LDL-C by about 60% and lowered MACE by 15% in FOURIER and ODYSSEY; the trials randomized 27,564 and 18,924 patients, respectively.
- Bempedoic acid in CLEAR Outcomes randomized 13,970 statin-intolerant/high-risk patients and reduced MACE by 13% (HR 0.87, 95% CI 0.79–0.96, p = 0.004) with a 21.1% greater LDL-C reduction versus placebo; pemafibrate lowered triglycerides by 26% in PROMINENT but did not significantly reduce MACE (HR 1.03, 95% CI 0.91–1.15).
Methods
- Narrative review of established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention, covering mechanism of action, developmental stage, safety, lipid effects, and cardiovascular outcomes.
- The authors state they conducted a keyword search to identify studies on established and emerging lipid-modifying drugs and summarized results in a narrative overview.
- Evidence synthesized includes guidelines, randomized controlled trials, meta-analyses, and ongoing cardiovascular outcomes trials.
Limitations
- The paper states that robust data for add-on therapies in primary cardiovascular prevention remain scarce.
- It also states that many new drugs still need to demonstrate safety, efficacy, and cost-effectiveness in randomized cardiovascular outcome trials before routine adoption.
- Evident from the text: this is a narrative review, so conclusions depend on heterogeneous studies and many outcomes are reported across different populations and follow-up periods rather than from one uniform analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
85 Valid · 16 Not valid · 31 Not checked · 13 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“For secondary prevention in hypertriglyceridemia, second-line options such as statin add-on or statin-intolerant treatments are icosapent ethyl and fenofibrate.”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Abstract Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events. Consequently, novel pharmaceutical drugs have been developed to control and modify the composition of blood lipids to ultimately prevent fatal cardiovascular events in patients with dyslipidaemia. This article reviews established and emerging lipid-lowering drugs regarding their mechanism of action, development stage, ongoing clinical trials, side effects, effect on blood lipids and reduction in cardiovascular morbidity and mortality. We conducted a keyword search to identify studies on established and emerging lipid modifying drugs. Results were summarized in a narrative overview. Established pharmaceutical treatment options include the Niemann-Pick-C1 like-1 protein (NPC1L1) inhibitor ezetimibe, the protein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab, fibrates as peroxisome proliferator receptor alpha (PPAR-α) activators, and the omega-3 fatty acid icosapent ethyl. Statins are recommended as the first-line therapy for primary and secondary cardiovascular prevention in patients with hypercholesterinaemia and hypertriglyceridemia. For secondary prevention in hypercholesterinaemia, second-line options such as statin add-on or statin-intolerant treatments are ezetimibe, alirocumab and evolocumab. For secondary prevention in hypertriglyceridemia, second-line options such as statin add-on or statin-intolerant treatments are icosapent ethyl and fenofibrate. Robust data for these add-on therapeutics in primary cardiovascular prevention remains scarce. Recent biotechnological advances have led to the development of innovative small molecules (bempedoic acid, lomitapide, pemafibrate, docosapentaenoic and eicosapentaenoic acid), antibodies (evinacumab), antisense oligonucleotides (mipomersen, volanesorsen, pelcarsen, olezarsen), small interfering RNA (inclisiran, olpasiran), and gene therapies for patients with dyslipidemia. These molecules specifically target new cellular pathways, such as the adenosine triphosphate-citrate lyase (bempedoic acid), PCSK9 (inclisiran), angiopoietin-like 3 (ANGPTL3: evinacumab), microsomal triglyceride transfer protein (MTP: lomitapide), apolipoprotein B-100 (ApoB-100: mipomersen), apolipoprotein C-III (ApoC-III: volanesorsen, olezarsen), and lipoprotein (a) (Lp(a): pelcarsen, olpasiran). The authors are hopeful that the development of new treatment modalities alongside new therapeutic targets will further reduce patients’ risk of adverse cardiovascular events. Apart from statins, data on new drugs’ use in primary cardiovascular prevention remain scarce. For their swift adoption into clinical routine, these treatments must demonstrate safety and efficacy as well as cost-effectiveness in randomized cardiovascular outcome trials.
What the sources say
- Partly supportedcites [19] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455. sourceExperimental — accuracy not yet measured
The drug-treatment recommendations for hypertriglyceridaemia consider icosapent ethyl with a statin for high-risk patients whose triglycerides remain elevated, and fenofibrate with a statin for certain patients who have reached their LDL-C goal. They do not present either drug as a statin-intolerance treatment; the statin-intolerance recommendations instead discuss ezetimibe and PCSK9 inhibitors. The claim also omits the conditions attached to the hypertriglyceridaemia recommendations. Page numbers were not available in our copy. (LLM, conf=0.88)
- Disputedcites [20] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143. https://doi.org/10.1161/CIR.0000000000000625. sourceExperimental — accuracy not yet measured
Section 3.1 (page unavailable) identifies fibrates as triglyceride-lowering drugs but says randomized trials do not support adding them to statin therapy—the opposite of presenting fenofibrate as a statin add-on for secondary prevention. The secondary-prevention guidance instead discusses ezetimibe and PCSK9 inhibitors as add-ons; the retrieved passages do not identify icosapent ethyl or fenofibrate as the claimed second-line options. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“For example, the recommended LDL-C level for very high-risk patients has been lowered from < 70 to < 55 mg/mL.”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Introduction
What the sources say
- Not checked — no full text of the sourcecites [18] Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8:36–49. https://doi.org/10.1016/S2213-8587(19)30388-2. source
- Partly supportedcites [19] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455. sourceExperimental — accuracy not yet measured
The LDL-C treatment-goals section recommends <55 mg/dL for very-high-risk patients. It does not establish that their previous goal was <70; it lists <70 mg/dL as the current goal for high-risk patients. The citing sentence also prints mg/mL, whereas the guideline uses mg/dL. (LLM, conf=0.88)
- Disputedcites [20] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143. https://doi.org/10.1161/CIR.0000000000000625. sourceExperimental — accuracy not yet measured
The guideline’s very-high-risk ASCVD recommendation (passage [1], page not specified) uses an LDL-C threshold of 70 mg/dL for considering additional treatment, not a lowered threshold of 55. Passage [7] likewise identifies ≥70 mg/dL as the trigger for adding nonstatin therapy. The guideline gives units in mg/dL, not mg/mL. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“These results were consistent across European countries [13–15].”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Introduction
What the sources say
- Disputedcites [13] Vrablik M, Seifert B, Parkhomenko A, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021;334:66–75. https://doi.org/10.1016/j.atherosclerosis.2021.08.035. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) explicitly reports marked differences in LDL-C goal attainment among the Central and Eastern European countries studied. Section 3.7 (page unavailable) also reports lower attainment in Central and Eastern Europe than in Northern and Western Europe. The paper therefore does not describe its results as consistent across European countries. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [14] Gouni-Berthold I, Schaper F, Schatz U, et al. Low-density lipoprotein cholesterol goal attainment in Germany: results from the DA VINCI study. Atheroscler Plus. 2022;50:10–6. https://doi.org/10.1016/j.athplu.2022.07.024. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says the main conclusion—a gap between guidelines and clinical practice—was confirmed in all countries. It also says LDL-C goal-attainment results differed by country, so it does not support the broader claim that the results generally were consistent. (LLM, conf=0.86)
- Partly supportedcites [15] van de Borne P, Peeters A, Janssens L, et al. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiol. 2022. https://doi.org/10.1080/00015385.2022.2030568. sourceExperimental — accuracy not yet measured
The Discussion (p. 8) says Belgian LDL-C goal-attainment results were generally in line with those for the overall European DA VINCI population. That supports similarity between Belgium and the European aggregate, but the paper does not establish that results were consistent across individual European countries. (LLM, conf=0.85)
plainn = 5,888- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Despite the widespread availability of low-cost statins, the majority of patients with dyslipidaemia do not attain adequate LDL-C levels by existing lifestyle modifications and pharmacological treatment strategies [7–11].”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Introduction
What the sources say
- Partly supportedcites [7] März W, Dippel F-W, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99–107. https://doi.org/10.1016/j.atherosclerosis.2017.11.020. sourceExperimental — accuracy not yet measured
The Results (p. 2) report that only 30% of the studied patients attained guideline-recommended LDL-C targets. But this was a German cohort selected for high or very-high cardiovascular risk, not patients with dyslipidaemia generally. The Discussion (p. 8) also reports that 63.7% received no current lipid-lowering therapy, so the study does not show that lifestyle modifications and pharmacological treatment failed for most patients. (LLM, conf=0.88)
- Disputedcites [8] Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis. 2012;224:150–3. https://doi.org/10.1016/j.atherosclerosis.2012.06.052. sourceExperimental — accuracy not yet measured
The Results report that 73% of the 9,955 patients attained their LDL-C goals, contrary to the claim that a majority did not. The paper reports lower attainment in some high-risk subgroups, but not in the overall study population; it also does not evaluate lifestyle modifications as a treatment strategy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [9] Kuiper JG, Sanchez RJ, Houben E, et al. Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands. Clin Ther. 2017;39:819-827.e1. https://doi.org/10.1016/j.clinthera.2017.03.001. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says only 19% of this Dutch high-cardiovascular-risk cohort met the stricter ESC/EAS LDL-C threshold, supporting substantial nonattainment. But the Results and Discussion say 55% met the Dutch guideline goal; the study does not establish that a majority of patients with dyslipidaemia generally fail to attain adequate levels, or assess lifestyle modifications. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [10] Chi MD, Vansomphone SS, Liu I-LA, et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20:e105-112.
- Partly supportedcites [11] Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 2005;28:595–9. https://doi.org/10.2337/diacare.28.3.595. sourceExperimental — accuracy not yet measured
The RESULTS section reports that only 44% of the study’s patients with diabetes and dyslipidemia reached their LDL-C goal. The MPR and LDL cholesterol goal attainment section also reports a survey in which 38% reached their targets. These passages support the majority-not-at-goal point, but they do not establish that lifestyle modifications were among the strategies used or assess the claim for all patients with dyslipidemia. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The cardioprotective effects of PCSK9 inhibitors were subsequently confirmed in other clinical trials and meta-analyses [80–85].”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Established Pharmaceutical Therapies > PCSK9 Inhibitors
What the sources say
- Not checked — no full text of the sourcecites [80] Schmidt AF, Carter J-PL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10:CD011748. https://doi.org/10.1002/14651858.CD011748.pub3. source
- Supportedcites [81] Karatasakis A, Danek BA, Karacsonyi J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017;6: e006910. https://doi.org/10.1161/JAHA.117.006910. source
The Discussion reports that this meta-analysis of 35 randomized trials found significant reductions in myocardial infarction, stroke, and coronary revascularization with PCSK9 inhibitors. That supports the cited statement about cardioprotective effects, although the paper found no significant mortality benefit. (LLM, conf=0.93)
- Partly supportedcites [82] Sahebkar A, Di Giosia P, Stamerra CA, et al. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol. 2016;81:1175–90. https://doi.org/10.1111/bcp.12905. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that preliminary data suggest PCSK9 inhibitors reduce cardiovascular events and says their effects on clinical outcomes have been established. But this meta-analysis measured hs-CRP, not cardiovascular outcomes; its own findings therefore do not confirm the cardioprotective effect attributed to it. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [83] Monami M, Sesti G, Mannucci E. PCSK9 inhibitor therapy: a systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab. 2019;21:903–8. https://doi.org/10.1111/dom.13599. source
- Disputedcites [84] Zhang X-L, Zhu Q-Q, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. https://doi.org/10.1186/s12916-015-0358-8. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that whether anti-PCSK9 antibodies improve cardiovascular outcomes “remains to be confirmed.” It reports lower cardiovascular-event risk in exploratory trial analyses, but says longer-term outcome trials are needed for definite answers. Thus this meta-analysis does not confirm the cardioprotective effect attributed to it. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Talasaz AH, Ho A-CJ, Bhatty F, et al. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy. 2021;41:1009–23. https://doi.org/10.1002/phar.2635. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
80 more claims · 55 with their cited sources checked
Create a free account to see all 145 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 48
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“For example, the recommended LDL-C level for very high-risk patients has been lowered from < 70 to < 55 mg/mL.”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Introduction
Reported 55 · recomputed 0.785714
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Abstract
“antisense oligonucleotides (mipomersen, volanesorsen, pelcarsen, olezarsen), small interfering RNA (inclisiran, olpasiran)”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Emerging Pharmaceutical Therapies > Pelacarsen
“Pelacarsen is a second-generation hepatocyte-directed antisense oligonucleotide that lowers Lp(a) levels [181].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Established Pharmaceutical Therapies
“AHA/ACC/multi-society guidelines specify that treatment with PSCK9 inhibitors should include a physician–patient discussion about the net benefit and cost, given that PCSK9 inhibitors were found to be of low value.”
§ Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention > Established Pharmaceutical Therapies
“PCSK9 inhibitors are recommended by both guidelines for secondary cardiovascular prevention in very high-risk patients who do not reach their LDL-C goal with maximum tolerated statin therapy and ezetimibe.”
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Research works printed but not linked: 2
- Ollendorf DA, McQueen RB, Campbell JD, et al. Additive therapies for cardiovascular disease: effectiveness and value. 2019.http://icer-review.org/material/cvd-final-evidence-report/. Accessed 22 Mar 2021.
- Amgen. Amgen announces positive topline phase 2 data for investigational olpasiran in adults with elevated lipoprotein(a). 2022. https://www.amgen.com/newsroom/press-releases/2022/05/amgen-announces-positive-topline-phase-2-data-for-investigational-olpasiran-in-adults-with-elevated-lipoproteina. Accessed 21 Sep 2022.
Cited by
Lipid metabolism in homeostasis and disease
Li, Z., Deng, W., Yang, L., Tang, C., Yue, J.-M., Monteiro, O., Baptista‐Hon, D. T., & Li, T. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02357-x · Cited by 73
“497 Pema fi brate is currently being explored for its potential in treating diabetic retinopathy, atrial fi brillation, and primary mitochondrial diseases.”
ApoB100 and Atherosclerosis: What’s New in the 21st Century?
Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Evangelopoulos, A. A., Panagopoulos, F., Stratigou, T., Geladari, E. V., Karampela, Ι., & Dalamaga, Μ. (2024) · Metabolites · doi:10.3390/metabo14020123 · Cited by 54
“Bempedoic acid’s safety and efficacy in patients with statin intolerance have been investigated in phase 3 CLEAR trials, showing that BA may promote a 12–19% reduction in ApoB100 [150].”
BackgroundToma, L., Deleanu, M., Sanda, G. M., Barbălată, T., Niculescu, L. S., Sima, A. V., & Stancu, C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084162 · Cited by 43
“Another class of drugs used for this purpose are Niemann-Pick C1-Like 1 (NPC1L1) inhibitors, such as ezetimibe, which inhibits the absorption of cholesterol in the intestine [143].”
BackgroundRegulatory effects of statins on Akt signaling for prevention of cancers
Hosseini, F. S., Ahmadi, A., Kesharwani, P., Hosseini, H., & Sahebkar, A. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111213 · Cited by 30
Lee, G., Yang, J., Kim, S., Tran, T., Lee, S. Y., Park, K. H., Kwon, S., Chung, K., Koh, J., Huh, Y. H., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42984 · Cited by 31
Metadata
- Authors
- Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T.
- Affiliations
- University Hospital Heidelberg (DE)
- LMU Klinikum (DE)
- TUM Klinikum (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Michaeli, Daniel Tobias
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2023-07-24
- Volume
- 23
- Issue
- 5
- Pages
- 477-495
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- PMC
- PMC10462544
- OpenAlex
- W4385186774
- Cited by
- 109
- References
- 207
- Citations by year
- 2026: 31 · 2025: 40 · 2024: 35 · 2023: 3
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by-nc)
- Funders
- Universitätsklinikum Heidelberg
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipid-lowering drugs, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cardiovascular disease prevention, statins, ezetimibe, PCSK9 inhibitors, fibrates, icosapent ethyl, fenofibrate, bempedoic acid, lomitapide, evinacumab, mipomersen, volanesorsen, olpasiran, inclisiran, olaparib, PCSK9, ANGPTL3, microsomal triglyceride transfer protein, LDL-C
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, Angiopoietin-Like Protein 3, Anticholesteremic Agents, Hypolipidemic Agents, Cardiovascular Diseases, Dicarboxylic Acids, Pharmaceutical Preparations, Fatty Acids, Humans, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. https://app.cochat.ai/papers/10.1007/s40256-023-00594-5
- The paper
- Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023). Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-023-00594-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.